Fortress Biotech, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lindsay A. Rosenwald
- Full Time Employees
- 78
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1111 Kane Concourse Bay Harbor Islands FL United States of America 33154
- IPO Date
- Nov 17, 2011
- CIK
- 0001429260
- Website
- fortressbiotech.com
- Similar Companies
- Business
- Fortress Biotech, Inc. Fortress Biotech, Inc. (Nasdaq: FBIO) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products across oncology, dermatology, rare diseases, and gene therapy; the company markets eight prescription products including Emrosi (minocycline hydrochloride extended-release capsules) for rosacea, Qbrexza (medicated cloth towelette) for primary axillary hyperhidrosis, Accutane (oral isotretinoin) for severe acne, Amzeeq (topical minocycline) for acne vulgaris, Zilxi for rosacea, and additional dermatology offerings through subsidiary Journey Medical Corporation, alongside development programs such as CUTX-101 (copper histidine injection) for Menkes disease and cosibelimab (UNLOXCYT) for advanced cutaneous squamous cell carcinoma. Founded in 2006 and headquartered in Bay Harbor Islands, Florida, Fortress operates through a network of majority-owned subsidiaries and partners including AstraZeneca, City of Hope, and Sentynl, with geographic focus on the United States and global clinical development activities. Recent developments include FDA approvals in late 2024 for Emrosi and UNLOXCYT, the 2025 commercial launch of Emrosi generating initial prescriptions and expanded payer coverage to 65% of commercial lives, the sale of subsidiary Checkpoint Therapeutics to Sun Pharma yielding approximately $28 million plus a 2.5% royalty on UNLOXCYT net sales and potential contingent value right payments up to $4.8 million, a strategic AI-driven collaboration with Partex NV in March 2025 for biopharmaceutical compound evaluation, and subsidiary Urica Therapeutics securing a $205 million Series A financing for Crystalys Therapeutics advancing dotinurad Phase 3 trials for gout with Fortress retaining equity and a 3% royalty.
Company News
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million